Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABA-201 in active systemic lupus erythematosus
2023-507613-10-01Phase 2Authorised
- Sponsor
- Cabaletta Bio
- Start
- Mar 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 4
01
Overview
Phase 2, open-label trial of resecabtagene autoleucel in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (2 arms), sponsored by Cabaletta Bio. Primary endpoint: Early safety after CABA-201 infusion. Planned start Mar 2025; status: authorised.
02
Drugs
resecabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on 2023-507613-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507613-10-01.